Literature DB >> 7561340

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction.

K C Parker1, M Shields, M DiBrino, A Brooks, J E Coligan.   

Abstract

The human mayor histocompatibility complex class I molecule HLA-A2 preferentially binds peptides that contain Leu at P2 and Val or Leu at the C terminus. The other amino acids in the peptide also contribute to binding positively or negatively. It is possible to estimate the binding stability of HLA-A2 complexes containing particular peptides by applying coefficients, deduced from a large amount of binding data, that quantify the relative contribution of each amino acid at each position. In this review, we describe the molecular basis for these coefficients and demonstrate that estimates of binding stability based on the coefficients are generally concordant with experimental measurements of binding affinities. Peptides that contained cysteine were predicted less well, possibly because of complications resulting from peptide dimerization and oxidation. Apparently, peptide binding affinity is largely controlled by the rate of dissociation of the HLA/peptide/beta 2-microglobulin complex, whereas the rate of formation of the complex has less impact on peptide affinity. Although peptides that bind tightly to HLA-A2, including many antigenic peptides bind much more weakly. Therefore, a full understanding of why certain peptides are immunodominant will require further research.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561340     DOI: 10.1007/BF02918496

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  129 in total

1.  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2.

Authors:  K C Parker; M A Bednarek; L K Hull; U Utz; B Cunningham; H J Zweerink; W E Biddison; J E Coligan
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

2.  Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle.

Authors:  H C Guo; T S Jardetzky; T P Garrett; W S Lane; J L Strominger; D C Wiley
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

3.  Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonist.

Authors:  M C Gammon; M A Bednarek; W E Biddison; S S Bondy; J D Hermes; G E Mark; A R Williamson; H J Zweerink
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

4.  Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules.

Authors:  A Sette; A Vitiello; P Farness; J Furze; J Sidney; J M Claverie; H M Grey; R Chesnut
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

Review 5.  Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.

Authors:  T Boon
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

6.  HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides.

Authors:  D N Garboczi; D T Hung; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

7.  Selectivity of MHC-encoded peptide transporters from human, mouse and rat.

Authors:  F Momburg; J Roelse; J C Howard; G W Butcher; G J Hämmerling; J J Neefjes
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

Review 8.  HLA class I binding regions of HIV-1 proteins.

Authors:  J Choppin; J G Guillet; J P Lévy
Journal:  Crit Rev Immunol       Date:  1992       Impact factor: 2.214

Review 9.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

10.  Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex.

Authors:  M Corr; L F Boyd; S R Frankel; S Kozlowski; E A Padlan; D H Margulies
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  19 in total

Review 1.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

2.  Side-chain conformational space analysis (SCSA): a multi conformation-based QSAR approach for modeling and prediction of protein-peptide binding affinities.

Authors:  Peng Zhou; Xiang Chen; Zhicai Shang
Journal:  J Comput Aided Mol Des       Date:  2008-10-08       Impact factor: 3.686

Review 3.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.

Authors:  B Li; Y Wang; J Chen; H Wu; W Chen
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

5.  Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.

Authors:  Katja Mauerer Zirlik; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

6.  Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.

Authors:  José A Guevara-Patiño; Manuel E Engelhorn; Mary Jo Turk; Cailian Liu; Fei Duan; Gabrielle Rizzuto; Adam D Cohen; Taha Merghoub; Jedd D Wolchok; Alan N Houghton
Journal:  J Clin Invest       Date:  2006-04-13       Impact factor: 14.808

7.  Proteomics in Vaccinology and Immunobiology: An Informatics Perspective of the Immunone.

Authors:  Irini A. Doytchinova; Paul Taylor; Darren R. Flower
Journal:  J Biomed Biotechnol       Date:  2003

8.  Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy.

Authors:  Yiping Chen; Jennifer Trofe; Jennifer Gordon; Renaud A Du Pasquier; Prabir Roy-Chaudhury; Marcelo J Kuroda; E Steve Woodle; Kamel Khalili; Igor J Koralnik
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Authors:  Matthias Leisegang; Boris Engels; Karin Schreiber; Poh Yin Yew; Kazuma Kiyotani; Christian Idel; Ainhoa Arina; Jaikumar Duraiswamy; Ralph R Weichselbaum; Wolfgang Uckert; Yusuke Nakamura; Hans Schreiber
Journal:  Clin Cancer Res       Date:  2015-12-14       Impact factor: 12.531

Review 10.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Authors:  Ravi A Madan; Philip M Arlen; Mahsa Mohebtash; James W Hodge; James L Gulley
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.